Please ensure Javascript is enabled for purposes of website accessibility

Why Sotera Health Stock Is Falling Today

By Keith Speights – Nov 10, 2021 at 1:36PM

Key Points

  • Sotera beat expectations with its Q3 revenue and earnings.
  • However, the company lowered the upper end of its full-year revenue guidance range.
  • Overall, Sotera's business continues to perform well despite some COVID-19 headwinds.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors weren't happy with the company's full-year guidance.

What happened

Shares of Sotera Health (SHC 2.50%) were falling 8.6% as of 12:36 p.m. EST on Wednesday and dropped as much as 12.8% earlier in the day. The decline came after the company announced its third-quarter results Wednesday morning.

Sotera reported revenue in the third quarter of $226 million, up 13% year over year and higher than the average analysts' estimate of $221.6 million. The company posted adjusted earnings per share (EPS) of $0.21. This result reflected improvement from adjusted EPS of $0.12 in the prior-year period. It also narrowly topped the consensus estimate of $0.20. 

With both revenue and earnings beats, why is the healthcare stock falling? Sotera narrowed its full-year 2021 revenue guidance. The company previously forecast revenue growth of between 12% and 15% but lowered the upper end of the range to 14%. Sotera now looks for 2021 revenue between $920 million and $930 million, below the average analysts' estimate of $932.9 million. 

Surgical instruments with surgeons in the background.

Image source: Getty Images.

So what

Sotera's business continues to perform well overall. The company's Sterigenics unit, which provides sterilization solutions, delivered year-over-year revenue growth of 15.1%. Its Nordion unit, which provides Cobalt-60 and gamma irradiation systems, generated even stronger revenue growth of 41.9%. However, sales for Sotera's Nelson Labs laboratory testing services business slipped 2.6% year over year due to lower demand for pandemic-related testing.

The company's guidance wasn't quite what investors hoped it would be. However, with Sotera's shares trading at nearly 26 times expected earnings, even minor disappointments are likely to cause the stock to slide.

Now what

Probably the main thing to watch with Sotera going forward is how COVID-19 impacts its business. The company is likely to see a slow recovery in medical device testing while demand for personal protective equipment continues to decline. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.